Similar drugsTo uncover Dosage form: & nbspSpray for topical application dosed Composition:Composition per 1 dose / per 100 g:Active substances:Cetylpyridinium chloride 0.500 mg / 0.250 gTetracaine hydrochloride - 0.034 mg / 0.017 gZinc sulfate monohydrate - 2.746 mg / 1.373 gExcipients: Glycerol 85% 80,000 mg / 40,000 g, ethanol 96% 60,000 mg / 30,000 g, sucrose 30,400 mg / 15,200 g, mint flavor 2,000 mg / 1,000 g, eucalyptus oil 1,000 mg / 0,500 g, flavoring " honey "- 0,200 mg / 0,100 g, purified water - up to 200 mg / up to 100 g. Description:Spray in a plastic bottle with a dosing valve. The contents of the cylinder are a colorless liquid with the smell of mint. Pharmacotherapeutic group:Antiseptic + local anesthetic. ATX: & nbspOther preparations for topical use in diseases of the oral cavity Pharmacodynamics:NOVOSEPT FORTE has a bactericidal, antifungal, and local anesthetic effect due to its active components: Cetylpyridinium chloride - antiseptic from the group of quaternary ammonium compounds, refers to cationic detergents. Has a bactericidal effect against a wide range of gram-positive and, to a lesser extent, gram-negative bacteria. The antimicrobial activity of cetylpyridinium chloride is due to its non-specific interaction with various components of the bacterial cell: membrane, ribosomes, proteins and enzymes,as a result of which osmotic balance, breathing, carbohydrate and protein metabolism are violated, and all this leads to the death of the bacterium. Cetylpyridinium chloride suppresses also some groups of viruses and fungi. Inactive against bacterial spores.Tetracaine hydrochloride - an effective local anesthetic, quickly removes or reduces the sensation of pain.Zinc - an oligoelement, has an immunomodulatory effect. Indications:Local treatment of inflammation of the mucous membranes of the oral cavity and pharynx: stomatitis, gingivitis, tonsillitis, pharyngitis. Contraindications:Hypersensitivity to drug components, local anesthetics, mucosal integrity disorder, acute renal or hepatic insufficiency, pregnancy, lactation period, children under 18 years of age. Dosing and Administration:Locally. The drug is sprayed on the mucous membrane of the mouth and throat when breathing is delayed.Adults: 3 injections per reception 4-6 times a day at intervals of 2 hours.The usual course of treatment is not more than five days. Side effects:Allergic reactions (hives, itching, anaphylactic shock, swallowing) are possible. Overdose:Symptoms: vomiting, pallor of the skin, bradycardia, depression of the respiratory center, apnea. In case of an overdose, it is necessary to cancel NOVOSEPT® FORTE and consult a doctor. Interaction:Drugs that inhibit cholinesterase (antimiasthenic, cyclophosphamide, demecarium, ecothiophate, insecticides, isoflurafate, thiotepa), reduce the metabolism of tetracaine hydrochloride and increase its toxicity.With simultaneous admission with anticoagulants (dalteparin, enoxaparin, heparin, warfarin) increases the risk of bleeding.When used with monoamine oxidase inhibitors (furazolidone, procarbazine, selegiline) increases the risk of lowering blood pressure.Tetracaine hydrochloride enhances and lengthens the effect of myorelaxing drugs.Beta-adrenoblockers slow down the metabolism of tetracaine hydrochloride, increasing its toxicity (decrease in hepatic blood flow).Zinc is incompatible with silver salts, quinine, ichthyol, citral (forms poorly soluble compounds), with alkaline-reacting substances (forms zinc oxide hydrate), with protargol (coagulated).Zinc reduces the absorption of tetracyclines, copper (should not be used until 2 hours after taking these medicines).Thiazide diuretics increase the excretion of zinc in the urine.Folic acid may impair the absorption of zinc to a small extent.High doses of iron, penicillamine and other complexing drugs significantly reduce zinc absorption (should not be used until 2 hours after taking these medicines).Cetylpyridinium is not compatible with anionic surfactants. Special instructions:If the disease is accompanied by fever, headache, nausea, and if there is no improvement within five days of treatment, you should consult your doctor. Long-term treatment (more than 5 days) can cause a disturbance of the balance of the natural microflora of the oral cavity and pharynx with the risk of developing pathogenic bacteria and fungi. Form release / dosage:Spray for topical use dosed. Packaging:For 25 ml (not less than 100 doses) in a plastic bottle with a dosing valve. For 1 bottle in a cardboard box with instructions for use. Storage conditions:At a temperature of no higher than 25 ° C.Keep out of the reach of children! Shelf life:2 years. Do not use after the expiration date. Terms of leave from pharmacies:On prescription Registration number:LSR-003704/10 Date of registration:04.05.2010 / 29.04.2014 The owner of the registration certificate:VALEANT, LLC VALEANT, LLC Russia Manufacturer: & nbspHERCEL B.V. Netherlands Representation: & nbspVALEANT LLC VALEANT LLC Russia Information update date: & nbsp2016-03-02 Illustrated instructions × Illustrated instructions Instructions